Nothing Special   »   [go: up one dir, main page]

WO2006108414A2 - Agent pour assurer la therapie et la prophylaxie de maladies de la peau - Google Patents

Agent pour assurer la therapie et la prophylaxie de maladies de la peau Download PDF

Info

Publication number
WO2006108414A2
WO2006108414A2 PCT/DE2006/000700 DE2006000700W WO2006108414A2 WO 2006108414 A2 WO2006108414 A2 WO 2006108414A2 DE 2006000700 W DE2006000700 W DE 2006000700W WO 2006108414 A2 WO2006108414 A2 WO 2006108414A2
Authority
WO
WIPO (PCT)
Prior art keywords
zeolite
composition according
psoriasis
calcium
agent
Prior art date
Application number
PCT/DE2006/000700
Other languages
German (de)
English (en)
Other versions
WO2006108414A3 (fr
Inventor
Jörg Schulz
Slavko Ivkovic
Tihomir Lelas
Peter Bendzko
Original Assignee
Klinomed Institut für angewandte Nanotechnologie und Nanomedizin GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinomed Institut für angewandte Nanotechnologie und Nanomedizin GmbH filed Critical Klinomed Institut für angewandte Nanotechnologie und Nanomedizin GmbH
Publication of WO2006108414A2 publication Critical patent/WO2006108414A2/fr
Publication of WO2006108414A3 publication Critical patent/WO2006108414A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams

Definitions

  • the invention relates to an agent for the therapy and prophylaxis of skin diseases, in particular psoriasis, neurodermatitis or atopic dermatitis and acne. Areas of application of the invention are the medicine and the food industry.
  • Psoriasis vulgaris is one of the most widespread diseases in industrialized countries. Psoriasis is a chronic, inflammatory disease of the skin and sometimes of the joints. It affects between one and three percent of the population and is thus one of the most common skin diseases.
  • Psoriasis is not an infectious disease and does not lead to an involvement of internal organs. But there is a genetic predisposition (genetic disposition).
  • Signs of psoriasis vulgaris are the typical skin changes. These are sharply demarcated reddish, slightly raised disease centers, which are covered by more or less dense silvery-white scales.
  • the size of the herd can vary widely from small pointy flocks to several palm-sized skin areas (plaques).
  • the superficial scales can be easily detached, the deeper ones, however, are stronger and can finally be considered as remove coherent, sheet-like cuticle. As a result, small, punctate skin bleeding occurs.
  • Psoriasis vulgaris can occur acutely, with numerous, drop to coin-sized psoriasis herds throughout the body.
  • psoriasis runs in batches, psoriasis can occur again and again after healing with therapy, or it can come in bursts to a worsening of psoriasis.
  • Various types of light therapy e.g., systemic PUVA therapy
  • systemic PUVA therapy e.g., systemic PUVA therapy
  • Systemic therapy options e.g., acitretin, methotrexate, cyclosporin A
  • psoriasis is currently not curable. Relapses of illness occur for life. In some patients, the disease is progressively progressive, with more and more skin involvement, while about two-thirds of psoriasis patients repeatedly experience periods when the disease does not appear.
  • the aim of the invention is to find new ways to treat skin diseases.
  • the invention has for its object to develop new means by which inflammatory skin diseases, especially psoriasis can be treated.
  • the Kemgedanke of the invention is to provide a means of zeolites and nettle extracts or calcium and / or magnesium salts for the treatment and prophylaxis of inflammatory skin diseases available.
  • the components of nettle extracts or calcium and / or magnesium salts can be used alone or as a mixture in a quantitative ratio of 1 to 99% to 99 to 1%.
  • Zeolites are natural minerals of volcanic origin, a total of over 20 natural species are known. The most interesting of the present invention are heulandite (also called clinoptilolite), natrolite and thomsonite. Physicochemically, zeolites can be characterized as crystalline hydrated alumino-silicates of alkali and alkaline-earth ions. Their ability to reversibly absorb and release water as well as exchange cations in the interstices makes it possible to use them as "molecular sieves".
  • zeolite preferably heulandite / clinoptilolite, having a particle size of less than 100 ⁇ m, preferably less than 5 ⁇ m, is used to prepare the agent according to the invention.
  • the starting material for the production of the second component nettle extract is the entire plant, preferably the leaves of the nettle. Both fresh nettles or nettle leaves and dried, in particular freeze-dried nettles or nettle leaves can be used.
  • the extraction of the fresh plant or its leaves is preferably carried out after freezing the plant or its leaves, for example in liquid nitrogen.
  • the nettles or nettle leaves are ground and extracted per kg with 5 l extractant. Extractants are water, ethanol, propanol or isopropanol or mixtures thereof.
  • the extraction can be carried out at temperatures between 10 and 7O 0 C, preferably the extraction is at room temperature.
  • the actual extraction process is straightforward and can be done in a conventional manner and using equipment known per se, for example by maceration or percolation.
  • the duration of the extraction depends on several factors (extractant, temperature, degree of comminution, type of extractor, etc.).
  • the end of the extraction process in a one-step process is achieved if the solids content of the extract remains constant, or in multi-step processes, when the solids content of the extract goes to zero. As a rule, the extraction takes between 12 and 72 hours.
  • the zeolite and nettle extract composition according to the invention is prepared by incubation of the zeolites in the nettle extract, which can optionally be diluted with extractant for this purpose.
  • the incubation is carried out with constant stirring and can take place at temperatures between 1 and 7O 0 C, preferably, the incubation at room temperature.
  • the duration of the incubation depends on the grain size of the zeolites. At a particle size of 50 microns saturation of the zeolites with the extract takes place within 3 hours, with a particle size of 5 microns within an hour.
  • the saturated with nettle extract zeolites may by suitable methods such as freeze drying or heating to 25 - 6O 0 C, preferably at 35-40 0 C to be dried.
  • the second component calcium and / or magnesium salts preferably consists of the corresponding carbonates, sulfates or chlorides.
  • the exact composition of the salts is variable.
  • dolomite is a natural calcium and magnesium carbonate used. The composition of this mineral varies depending on the place of origin. For example, Jurassic dolomite consists of 55% calcium carbonate and 43% magnesium carbonate, whereas Semmering's dolomite consists of 4% calcium carbonate and 90% magnesium carbonate.
  • the invention 'means using calcium and / or magnesium salts can be prepared in two different ways.
  • the first possibility is to incubate the zeolites with saturated solutions of the salts.
  • the incubation is carried out with constant stirring and can take place at temperatures between 1 and 7O 0 C, preferably, the incubation at room temperature.
  • the duration of the incubation depends on the grain size of the zeolites. With a grain size of 50 microns saturation of the zeolites with the extract takes place within 3 hours, with a grain size of 5 microns within one hour.
  • the saturated with the calcium and / or magnesium salts zeolites may by suitable methods such as freeze drying or heating to 25-90 0 C, preferably at 35 - 4O 0 C to be dried.
  • the second manufacturing method of the agent using calcium and / or magnesium salts is to pulverize these salts and to intimately mix with the zeolites according to the usual methods. This can be done for example in a mill. The mixing process is completed as soon as a homogeneous mixture is formed, which is usually the case after about 30 minutes.
  • the agent according to the invention is particularly suitable for the therapy and prophylaxis of special forms of psoriasis such as psoriasis of the palms and soles, nail psoriasis, erythrodermatic form of psoriasis, psoriasis pustulosa or psoriasis arthropathica, which are particularly resistant to treatment in the prior art.
  • special forms of psoriasis such as psoriasis of the palms and soles, nail psoriasis, erythrodermatic form of psoriasis, psoriasis pustulosa or psoriasis arthropathica, which are particularly resistant to treatment in the prior art.
  • zeolites one or more zeolite types heulandite / clinoptilolite, natrolite and thomsonite can be used.
  • micronized heulandite / clinoptilolite having a particle diameter of less than 5 ⁇ m is used.
  • the nettle extract is made from stinging nettles of the genus Urtica dioica (Great nettle) and / or Urtica urens (Small stinging nettle).
  • the corresponding carbonates, sulfates and / or chlorides can be used.
  • the natural mineral dolomite is used.
  • the agent according to the invention may also contain plant immunomodulators as further substances.
  • the zeolite content is between 1% and 95% with a proportion of the nettle extract or the calcium and / or magnesium salts of 5% to 80%.
  • the proportions for zeolite are 40-80% and for the nettle extract or the calcium and / or magnesium salts 20-60%.
  • Particularly suitable is an agent with a proportion of zeolite of 50-80% and a content of nettle extract or the calcium and / or magnesium salts of 1-20%.
  • the agent according to the invention can be administered in the form of a dietary supplement.
  • the treatment can be assisted by the use of 100% zeolite powder and / or zeolite-containing lotion and / or bathing in zeolite-containing bath salt.
  • the administration of the agent may be by oral ingestion and / or by application to the skin, for which purpose the agent may be in the form of powders, tablets, capsules, cream, milk, gel, emulsion, soap, shampoo or in aqueous form.
  • zeolite and nettle extract or calcium and / or magnesium salts leads to an unexpected increase in the therapeutic effect, as a study on psoriasis patients made clear.
  • 5 - 2g of the agent according to the invention with a ratio of 75% zeolite to 25% nettle extract resulted in a normalization of up to 50% of the affected skin areas.
  • normalization can be achieved up to 100%.
  • a total of 20 patients with confirmed psoriasis vulgaris were evaluated at a dermatological practice in Crivitz and subjected to a 12-week treatment with 3 x 2 capsules Megamin forte a 500 mg daily.
  • Megamin forte capsules contain 75% micronized heulandite / clinoptilolite with a particle diameter of less than 5 ⁇ m (EP1316530) and 25% nettle extract or powdered dolomite or a mixture of these two components.
  • the extract was made by maceration from leaves of stinging nettle Urtica dioica prepared by extraction with isopropanol at room temperature for 24 hours.
  • a total of 20 patients with confirmed psoriasis vulgaris were evaluated at a dermatological practice in Crivitz and subjected to a 12-week treatment with 3 x 2 Megamin forte a 500 mg capsules daily.
  • twice daily the topical application of the affected skin areas with zeolite powder and zeolite-containing ointment and 1-2 times a week a bath with zeolite-containing bath salts.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un agent utilisé pour assurer la thérapie et la prophylaxie de maladies de la peau, notamment du psoriasis, de la neurodermite ou de la dermite atopique. L'invention se caractérise en ce qu'elle vise à mettre au point un agent à base de zéolithes et d'extraits de grande ortie et de sels de calcium et/ou de magnésium. L'administration dudit agent peut s'effectuer par prise orale et/ou par traitement topique de la peau.
PCT/DE2006/000700 2005-04-15 2006-04-18 Agent pour assurer la therapie et la prophylaxie de maladies de la peau WO2006108414A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102005017730.1 2005-04-15
DE102005017730 2005-04-15
DE102005020467A DE102005020467A1 (de) 2005-04-15 2005-04-29 Mittel zur Therapie und Prophylaxe von Hauterkrankungen
DE102005020467.8 2005-04-29

Publications (2)

Publication Number Publication Date
WO2006108414A2 true WO2006108414A2 (fr) 2006-10-19
WO2006108414A3 WO2006108414A3 (fr) 2007-03-08

Family

ID=36951516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2006/000700 WO2006108414A2 (fr) 2005-04-15 2006-04-18 Agent pour assurer la therapie et la prophylaxie de maladies de la peau

Country Status (2)

Country Link
DE (1) DE102005020467A1 (fr)
WO (1) WO2006108414A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149375A1 (fr) 2008-07-28 2010-02-03 Despharma Kft. Compositions pour le traitement de maladies dermatologiques et leurs utilisations
AT511961B1 (de) * 2011-11-15 2013-04-15 Ipus Mineral & Umwelttechnologie Gmbh Wässrige paste zur äusseren anwendung auf euter von milchproduzierenden nutztieren
WO2014086893A1 (fr) 2012-12-04 2014-06-12 Purmin Gmbh Hydrogels ou suspensions de géopolymères ainsi que composites minéraux granulaires stables en position avec une part colloïdale, procédés pour leur préparation et utilisation
WO2023220768A1 (fr) * 2022-05-17 2023-11-23 Stritech Holdings Pty Ltd Formulations de lutte contre l'acné

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3482745A1 (fr) * 2017-11-08 2019-05-15 Dn 360 S.R.L. Composé de calcium à libération contrôlée administré par voie orale et son procédé de préparation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57134408A (en) * 1981-02-13 1982-08-19 Minato Sangyo Kk Skin activating agent
JPH06293613A (ja) * 1994-02-17 1994-10-21 Hakugen:Kk 衣類防虫剤
WO2002100420A2 (fr) * 2001-06-08 2002-12-19 Universita' Degli Studi Di Napoli 'federico Ii' Compositions pharmaceutiques a base de zeolite contenant du zinc et de l'erythromycine, destinees au traitement de l'acne
WO2004037220A1 (fr) * 2002-10-25 2004-05-06 Shiseido Company, Ltd. Preparations destinees a la peau, pour utilisation externe
US20050031708A1 (en) * 2003-08-06 2005-02-10 Portney Micah S. Composition comprising a zeolite compound for treatment of diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6475407A (en) * 1987-09-14 1989-03-22 Soft Silica Kk Bacteriostatic agent and germination and rooting promoting agent for directly sowed paddy rice seed
JP2003092998A (ja) * 2001-09-25 2003-04-02 Harumi Sangyo Kk 家畜類の養殖用飼料

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57134408A (en) * 1981-02-13 1982-08-19 Minato Sangyo Kk Skin activating agent
JPH06293613A (ja) * 1994-02-17 1994-10-21 Hakugen:Kk 衣類防虫剤
WO2002100420A2 (fr) * 2001-06-08 2002-12-19 Universita' Degli Studi Di Napoli 'federico Ii' Compositions pharmaceutiques a base de zeolite contenant du zinc et de l'erythromycine, destinees au traitement de l'acne
WO2004037220A1 (fr) * 2002-10-25 2004-05-06 Shiseido Company, Ltd. Preparations destinees a la peau, pour utilisation externe
US20050031708A1 (en) * 2003-08-06 2005-02-10 Portney Micah S. Composition comprising a zeolite compound for treatment of diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANZE M. ET AL.: "Development of newly formulated antimicrobial wound dressing (non woven sheet of Ag-Zn Zeolite impregnated Ca-Alginate fiber: A multi-centric clinical study" JAPANESE PHARMACOLOGY AND THERAPEUTICS, Bd. 27, Nr. 4, 1999, Seiten 215-245, XP009072325 JP *
DATABASE WPI Week 198918 Derwent Publications Ltd., London, GB; AN 1989-132529 XP002360292 "Compsn. for application to seeds before sowing in paddy field - contains clay silicate and/or (artificial) zeolite, and calcium peroxide, to accelerate germination and root generation and kill bacteria" & JP 01 075407 A (SOFT SILICA KK) 22. März 1989 (1989-03-22) *
DATABASE WPI Week 200363 Derwent Publications Ltd., London, GB; AN 2003-666418 XP002329003 "Fodder for livestock such as cows and pigs, comprises natural zeolite and materials such as silica, alumina, calcium blended with natural minerals such as zinc, magnesium and iron" & JP 2003 092998 A (HARUMI SANGYO KK) 2. April 2003 (2003-04-02) *
MIYASATO, K. ET AL.: "A newly developed wound dressing made of alginate fiber containing zeolite substituted by silver and zinc" JAPANESE PHARMACOLOGY AND THERAPEUTICS, Bd. 27, Nr. 4, 1999, Seiten 177-203, XP009072324 JP *
SVERKO V. ET AL.: "Natural Micronised Clinoptilolite Mixtures with Urtica dioica L. Extract as Possible Antioxidants" FOOD TECHNOLOGY AND BIOTECHNOLOGY, Bd. 42, Nr. 3, Juli 2004 (2004-07), Seiten 189-192, XP009072328 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149375A1 (fr) 2008-07-28 2010-02-03 Despharma Kft. Compositions pour le traitement de maladies dermatologiques et leurs utilisations
JP2011529098A (ja) * 2008-07-28 2011-12-01 デスファルマ エジェースシェーゲージュイ ソルガールタトー コルラートルト フェレレーシュシェーギュー タルシャシャーグ 皮膚疾患／粘膜疾患の予防及び治療のための組成物、及びその使用
US20150118314A1 (en) * 2008-07-28 2015-04-30 Despharma Kft. Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
JP2015096506A (ja) * 2008-07-28 2015-05-21 デスファルマ エジェースシェーゲージュイ ソルガールタトー コルラートルト フェレレーシュシェーギュー タルシャシャーグＤｅｓｐｈａｒｍａ Ｅｇｅｓｚｓｅｇｕｇｙｉ Ｓｚｏｌｇａｌｔａｔｏ Ｋｏｒｌａｔｏｌｔ Ｆｅｌｅｌｏｓｓｅｇｕ Ｔａｒｓａｓａｇ 皮膚疾患／粘膜疾患の予防及び治療のための組成物、及びその使用
AU2009275936B2 (en) * 2008-07-28 2016-02-18 Despharma Egeszegugyi Szolgaltato Korlatolt Felelossegu Tarsasag Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
AU2009275936A8 (en) * 2008-07-28 2016-02-18 Despharma Egeszegugyi Szolgaltato Korlatolt Felelossegu Tarsasag Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
EA025440B1 (ru) * 2008-07-28 2016-12-30 Дешпхарма Егешжегюгьи Сольгальтато Корлатольт Фелелёшшегю Таршашаг Композиции для профилактики и лечения дерматологических заболеваний/заболеваний слизистой и их применение
AT511961B1 (de) * 2011-11-15 2013-04-15 Ipus Mineral & Umwelttechnologie Gmbh Wässrige paste zur äusseren anwendung auf euter von milchproduzierenden nutztieren
AT511961A4 (de) * 2011-11-15 2013-04-15 Ipus Mineral & Umwelttechnologie Gmbh Wässrige paste zur äusseren anwendung auf euter von milchproduzierenden nutztieren
WO2014086893A1 (fr) 2012-12-04 2014-06-12 Purmin Gmbh Hydrogels ou suspensions de géopolymères ainsi que composites minéraux granulaires stables en position avec une part colloïdale, procédés pour leur préparation et utilisation
WO2023220768A1 (fr) * 2022-05-17 2023-11-23 Stritech Holdings Pty Ltd Formulations de lutte contre l'acné

Also Published As

Publication number Publication date
DE102005020467A1 (de) 2006-10-19
WO2006108414A3 (fr) 2007-03-08

Similar Documents

Publication Publication Date Title
EP1073445B1 (fr) Melange de substances pour application topique comprenant du miel et de l'huile d'olive
DE19831798A1 (de) Mittel zur Pflege und/oder Behandlung von Haut und Gewebe
DE69907606T2 (de) Zusammensetzung, die Panax pseudo ginseng und Eucommiae ulmoides enthält
DE69825279T2 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
WO2006108414A2 (fr) Agent pour assurer la therapie et la prophylaxie de maladies de la peau
EP0037488B1 (fr) Composition pharmaceutique pour la guérison des affections inflammatoires et/ou dégénératives et/ou atrophiées des membranes muqueuses
DE2113215A1 (de) Therapeutisches Kompositum
DE102008036725A1 (de) Pharmazeutische Zusammensetzung für die nasale Applikation
WO2000059519A2 (fr) Substance active et combinaison de substances actives pour l'homme et les animaux
EP1628671A1 (fr) Pierre pulverisee, en particulier medicament a base de poudre de dolomie, pour traiter des pathologies cancereuses
EP1911464B1 (fr) Préparation de base de type gel à base de mélanges d'huiles essentielles destinées à l'application dermique et transdermique
DE202016106651U1 (de) Entzündungshemmende Komposition aus Cannabidiol und Betulin
DE102005021382A1 (de) Mittel zur Therapie und Prophylaxe von Hauterkrankungen
EP3299026A1 (fr) Extraits de graines d'especes d'aframomum et leurs utilisation
WO2006122541A2 (fr) Composition d'action pharmaceutique destinee au traitement de diabetes
EP0256353A2 (fr) Traitement pharmaceutique contre une mauvaise absorption d'aliments ou de médicaments oraux
EP0265662A2 (fr) Composition pharmaceutique
DE202006018518U1 (de) Wasser- und emulgatorenfreie Sanddorn-Hautpflegepräparate
DE202007004981U1 (de) Zusammensetzung, insbesondere für die topische Behandlung von Hauterkrankungen
LU501504B1 (de) Pulverförmiges nahrungsergänzungsmittel zur herstellung eines getränks
WO2011070096A1 (fr) Composition pour le traitement de troubles gastro-intestinaux
DE19910697C2 (de) Verfahren zur Herstellung einer therapeutisch wirksamen Substanz und Verwendung derselben
DE20320103U1 (de) Pharmazeutische Zubereitung zur topischen Behandlung von Hauterkrankungen
DE102023124464A1 (de) Kosmetische oder dermatologische Zubereitung und Verfahren zur Herstellung einer solchen Zubereitung
DE102004034747B4 (de) Salbenzubereitung geeignet bei neurodermitischen Hauterkrankungen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06722818

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6722818

Country of ref document: EP